Compared with standard‐of‐care, GLP‐1 or GIP/GLP‐1 RAs were associated with a significantly lower risk of papilledema (RR: 0.25; 95% CI: 0.15–0.43; p < 0.01) and visual disturbances or blindness (RR: 0.41; 95% CI: 0.18–0.92; p = 0.03), and a near‐significant trend toward reduced headache risk (RR: 0.61; 95% CI: 0.34–1.07; p = 0.08). The gene discussed is GLP1R; the disease is optic papillitis.